Targeting innate immunity protein kinase signalling in inflammation

Nature Reviews Drug Discovery

Volumn 8, Issue 6, 2009, Pages 480-499

  Gaestel, Matthias ^a   Kotlyarov, Alexey ^a   Kracht, Michael ^b  

^a HANNOVER MEDICAL SCHOOL   (Germany)

^b JUSTUS LIEBIG UNIVERSITY GIESSEN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

5 (2,6 DICHLOROPHENYL) 2 (2,4 DIFLUOROPHENYLTHIO)PYRIMIDO[1,6 B]PYRIDAZIN 6 ONE; ABATACEPT; ADALIMUMAB; AZATHIOPRINE; CERTOLIZUMAB PEGOL; CYCLOPHOSPHAMIDE; CYTOKINE ANTIBODY; DISEASE MODIFYING ANTIRHEUMATIC DRUG; DORAMAPIMOD; ENZYME INHIBITOR; ETANERCEPT; GLUCOCORTICOID; I KAPPA B KINASE INHIBITOR; IMATINIB; INFLIXIMAB; INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; JANUS KINASE INHIBITOR; MAB THERA; METHOTREXATE; MITOGEN ACTIVATED PROTEIN KINASE P38 ALPHA INHIBITOR; NONSTEROID ANTIINFLAMMATORY AGENT; PROTEIN KINASE INHIBITOR; PROTEIN KINASE SYK INHIBITOR; RECOMBINANT INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; RILONACEPT; RITUXIMAB; STAUROSPORINE; STELARA; TUMOR NECROSIS FACTOR INHIBITOR; UNCLASSIFIED DRUG; USTEKINUMAB; VX 702;

ADAPTIVE IMMUNITY; ANKYLOSING SPONDYLITIS; ANTIINFLAMMATORY ACTIVITY; ARTHRITIS; AUTOIMMUNE DISEASE; AUTOINFLAMMATORY DISEASE; CANCER RISK; CHRONIC INFLAMMATION; CINCA SYNDROME; CLINICAL TRIAL; COLON CARCINOMA; CROHN DISEASE; CYTOKINE PRODUCTION; DRUG DESIGN; DRUG ERUPTION; DRUG MECHANISM; DRUG MEGADOSE; DRUG POTENCY; DRUG SCREENING; DRUG SPECIFICITY; DRUG STRUCTURE; DRUG SYNTHESIS; DRUG TARGETING; DRUG WITHDRAWAL; ENZYME PHOSPHORYLATION; FAMILIAL COLD AUTOINFLAMMATORY SYNDROME; FAMILIAL MEDITERRANEAN FEVER; GENE MUTATION; GOUT; HISTAMINE RELEASE; HOMEOSTASIS; HUMAN; HYPERIMMUNOGLOBULINEMIA D AND PERIODIC FEVER SYNDROME; IMMUNOREGULATION; INFLAMMATION; INNATE IMMUNITY; INTESTINE TUMOR; JUVENILE RHEUMATOID ARTHRITIS; LIVER CARCINOGENESIS; LIVER TOXICITY; LONG TERM CARE; LOW DRUG DOSE; MOLECULAR DOCKING; MOLECULAR MECHANICS; MOLECULAR RECOGNITION; MUCKLE WELLS SYNDROME; NECROTIZING ARTERITIS; NEUROTOXICITY; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PRIORITY JOURNAL; PRODUCT DEVELOPMENT; PROTEIN PROTEIN INTERACTION; PROTEIN TARGETING; PSORIASIS; REVIEW; RHEUMATOID ARTHRITIS; SIDE EFFECT; SIGNAL TRANSDUCTION; STRUCTURE ACTIVITY RELATION; UBIQUITINATION; UNSPECIFIED SIDE EFFECT;

ANIMALS; DRUG DELIVERY SYSTEMS; HUMANS; IMMUNITY, INNATE; INFLAMMATION; INFLAMMATION MEDIATORS; PROTEIN KINASE INHIBITORS; PROTEIN KINASES; SIGNAL TRANSDUCTION;

EID: 66749134594     PISSN: 14741776     EISSN: 14741784     Source Type: Journal    
DOI: 10.1038/nrd2829     Document Type: Review

References (195)

1. Smolen, J. S. & Steiner, G. Therapeutic strategies for rheumatoid arthritis. Nature Rev. Drug Discov. 2, 473-488 (2003).
2. Nathan, C. Points of control in inflammation. Nature 420, 846-852 (2002).
3. Cohen, P. Protein kinases - the major drug targets of the twenty-first century? Nature Rev. Drug Discov. 1, 309-315 (2002).
4. Kawagoe, T. et al. Sequential control of Toll-like receptor-dependent responses by IRAK1 and IRAK2. Nature Immunol. 9, 684-691 (2008).
5. Heinrichsdorff, J., Luedde, T., Perdiguero, E., Nebreda, A. R. & Pasparakis, M. p38α MAPK inhibits JNK activation and collaborates with IκB kinase 2 to prevent endotoxin-induced liver failure. EMBO Rep. 9, 1048-1054 (2008).
6. Kang, Y. J. et al. Macrophage deletion of p38α partially impairs lipopolysaccharide-induced cellular activation. J. Immunol. 180 5075-5082 (2008).
7. Kim, C. et al. The kinase p38α serves cell type-specific inflammatory functions in skin injury and coordinates pro- and anti-inflammatory gene expression. Nature Immunol. 9, 1019-1027 (2008).
8. Ventura, J. J. et al. p38α MAP kinase is essential in lung stem and progenitor cell proliferation and differentiation. Nature Genet. 39, 750-758 (2007).
9. Tang, M. et al. TAK1 is required for the survival of hematopoietic cells and hepatocytes in mice. J. Exp. Med. 205, 1611-1619 (2008).
10. Kajino-Sakamoto, R. et al. Enterocyte-derived TAK1 signaling prevents epithelium apoptosis and the development of ileitis and colitis. J. Immunol. 181, 1143-1152 (2008).
11. Fong, C. H. et al. An antiinflammatory role for IKKβ through the inhibition of "classical" macrophage activation. J. Exp. Med. 205, 1269-1276 (2008).
12. Ronkina, N. et al. The mitogen-activated protein kinase (MAPK)-activated protein kinases MK2 and MK3 cooperate in stimulation of tumor necrosis factor biosynthesis and stabilization of p38 MAPK. Mol. Cell. Biol. 27, 170-181 (2007).
13. Ananieva, O. et al. The kinases MSK1 and MSK2 act as negative regulators of Toll-like receptor signaling. Nature Immunol. 9 1028-1036 (2008).
14. Kim, T. W. et al. A critical role for IRAK4 kinase activity in Toll-like receptor-mediated innate immunity. J. Exp.Med. 204 1025-1036 (2007).
15. Lawrence, T., Bebien, M., Liu, G. Y., Nizet, V. & Karin, M. IKKα limits macrophage NF-κB activation and contributes to the resolution of inflammation. Nature 434, 1138-1143 (2005).
16. Karaman, M. W. et al. A quantitative analysis of kinase inhibitor selectivity. Nature Biotech. 26, 127-132 (2008).
17. Bain, J. et al. The selectivity of protein kinase inhibitors: A further update. Biochem. J. 408, 297-315 (2007).
18. Bantscheff, M. et al. Quantitative chemical proteomics reveals mechanisms of action of clinical ABL kinase inhibitors. Nature Biotech. 25, 1035-1044 (2007).
19. Thiel, M. J. et al. Central role of the MEK/ERK MAP kinase pathway in a mouse model of rheumatoid arthritis: Potential proinflammatory mechanisms. Arthritis Rheum. 56, 3347-3357 (2007).
20. Green, N. et al. Inhibitors of tumor progression loci-2 (Tpl2) kinase and tumor necrosis factor α (TNF-α) production: Selectivity and in vivo antiinflammatory activity of novel 8-substituted-4-anilino-6-aminoquinol ine-3-carbonitriles. J. Med. Chem. 50, 4728-4745 (2007).
21. Milici, A. J., Kudlacz, E. M., Audoly, L., Zwillich, S. & Changelian, P. Cartilage preservation by inhibition of Janus kinase 3 in two rodent models of rheumatoid arthritis. Arthritis Res. Ther. 10, R14 (2008).
22. Martin, M. W. et al. Structure-based design of novel 2-amino-6-phenyl-pyrimido[5′,4′:5,6]pyrimido[1,2-a] benzimidazol-5(6H)-ones as potent and orally active inhibitors of lymphocyte specific kinase (Lck): Synthesis, SAR, and in vivo anti-inflammatory activity. J. Med. Chem. 51, 1637-1648 (2008).
23. Mihara, K. et al. A potent and selective p38 inhibitor protects against bone damage in murine collagen-induced arthritis: A comparison with neutralization of mouse TNFα. Br. J. Pharmacol. 154, 153-164 (2008).
24. Anderson, D. R. et al. Pyrrolopyridine inhibitors of mitogen-activated protein kinase-activated protein kinase 2 (MK-2). J. Med. Chem. 50, 2647-2654 (2007).
25. Medicherla, S. et al. p38α-selective mitogen-activated protein kinase inhibitor SD-282 reduces inflammation in a subchronic model of tobacco smoke-induced airway inflammation. J. Pharmacol. Exp. Ther. 324, 921-929 (2008).
26. Ohori, M., Takeuchi, M., Maruki, R., Nakajima, H. & Miyake, H. FR180204, a novel and selective inhibitor of extracellular signal-regulated kinase, ameliorates collagen-induced arthritis in mice. Naunyn Schmiede bergs Arch. Pharmacol. 374, 311-316 (2007).
27. Sato, S. et al. Essential function for the kinase TAK1 in innate and adaptive immune responses. Nature Immunol. 6, 1087-1095 (2005).
28. Mendoza, H. et al. Roles for TAB1 in regulating the IL-1-dependent phosphorylation of the TAB3 regulatory subunit and activity of the TAK1 complex. Biochem. J. 409, 711-722 (2008).
29. Hayden, M. S. & Ghosh, S. Shared principles in NF-κB signaling. Cell 132, 344-362 (2008).
30. Vallabhapurapu, S. et al. Nonredundant and complementary functions of TRAF2 and TRAF3 in a ubiquitination cascade that activates NIK-dependent alternative NF-κB signaling. Nature Immunol. 9 1364-1370 (2008).
31. Kanayama, A. et al. TAB2 and TAB3 activate the NF-κB pathway through binding to polyubiquitin chains. Mol. Cell 15, 535-548 (2004).
32. Wertz, I. E. et al. De-ubiquitination and ubiquitin ligase domains of A20 downregulate NF-κB signalling. Nature 430, 694-699 (2004).
33. Windheim, M., Stafford, M., Peggie, M. & Cohen, P. Interleukin-1 (IL-1) induces the Lys63-linked polyubiquitination of IL-1 receptor-associated kinase 1 to facilitate NEMO binding and the activation of IκBα kinase. Mol. Cell. Biol. 28, 1783-1791 (2008).
34. Newton, K. et al. Ubiquitin chain editing revealed by polyubiquitin linkage-specific antibodies. Cell 134, 668-678 (2008).
35. Natoli, G., Saccani, S., Bosisio, D. & Marazzi, I. Interactions of NF-κB with chromatin: The art of being at the right place at the right time. Nature Immunol. 6, 439-445 (2005).
36. Wolter, S. et al. c-Jun controls histone modifications, NF-κB recruitment, and RNA polymerase II function to activate the ccl2 gene. Mol. Cell. Biol. 28, 4407-4423 (2008).
37. Gaestel, M. MAPKAP kinases - MKs - two's company, three's a crowd. Nature Rev. Mol. Cell Biol. 7, 120-130 (2006).
38. Yamaoka, K., Min, B., Zhou, Y. J., Paul, W. E. & O'Shea, J. J. Jak3 negatively regulates dendritic-cell cytokine production and survival. Blood 106, 3227-3233 (2005).
39. Karaghiosoff, M. et al. Central role for type I interferons and Tyk2 in lipopolysaccharide-induced endotoxin shock. Nature Immunol. 4, 471-477 (2003).
40. Correll, P. H. et al. Deregulated inflammatory response in mice lacking the STK/RON receptor tyrosine kinase. Genes Funct. 1 69-83 (1997).
41. Rothlin, C. V., Ghosh, S., Zuniga, E. I., Oldstone, M. B. & Lemke, G. TAM receptors are pleiotropic inhibitors of the innate immune response. Cell 131, 1124-1136 (2007).
42. Dennehy, K. M. et al. Syk kinase is required for collaborative cytokine production induced through Dectin-1 and Toll-like receptors. Eur. J. Immunol. 38, 500-506 (2008).
43. Doyle, S. L., Jefferies, C. A. & O'Neill, L. A. Bruton's tyrosine kinase is involved in p65-mediated transactivation and phosphorylation of p65 on serine 536 during NFκB activation by lipopolysaccharide. J. Biol. Chem. 280, 23496-23501 (2005).
44. Horwood, N. J. et al. Bruton's tyrosine kinase is required for lipopolysaccharide-induced tumor necrosis factor α production. J. Exp. Med. 197, 1603-1611 (2003).
45. Juurikivi, A. et al. Inhibition of c-kit tyrosine kinase by imatinib mesylate induces apoptosis in mast cells in rheumatoid synovia: a potential approach to the treatment of arthritis. Ann. Rheum. Dis. 64, 1126-1131 (2005).
46. Paniagua, R. T. et al. Selective tyrosine kinase inhibition by imatinib mesylate for the treatment of autoimmune arthritis. J. Clin. Invest. 116, 2633-2642 (2006).
47. Rommel, C., Camps, M. & Ji, H. PI3Kδ and PI3Kγ: Partners in crime in inflammation in rheumatoid arthritis and beyond? Nature Rev. Immunol. 7, 191-201 (2007).
48. Zhang, Y., Saccani, S., Shin, H. & Nikolajczyk, B. S. Dynamic protein associations define two phases of IL-1β transcriptional activation. J. Immunol. 181, 503-512 (2008).
49. Feldmeyer, L. et al. The inflammasome mediates UVB-induced activation and secretion of interleukin-1β by keratinocytes. Curr. Biol. 17, 1140-1145 (2007).
50. Greten, F. R. NF-κB is a negative regulator of IL-1β secretion as revealed by genetic and pharmacological inhibition of IKKβ. Cell 130, 918-931 (2007).
51. Petrilli, V., Dostert, C., Muruve, D. A. & Tschopp, J. The inflammasome: a danger sensing complex triggering innate immunity. Curr. Opin. Immunol. 19, 615-622 (2007).
52. Solle, M. et al. Altered cytokine production in mice lacking P2X7 receptors. J. Biol. Chem. 276, 125-132 (2001).
53. Keller, M., Ruegg, A., Werner, S. & Beer, H. D. Active caspase-1 is a regulator of unconventional protein secretion. Cell 132, 818-831 (2008).
54. O'Dea, E. L., Kearns, J. D. & Hoffmann, A. UV as an amplifier rather than inducer of NF-κB activity. Mol. Cell 30, 632-641 (2008).
55. Martinon, F., Petrilli, V., Mayor, A., Tardivel, A. & Tschopp, J. Gout-associated uric acid crystals activate the NALP3 inflammasome. Nature 440, 237-241 (2006).
56. Hornung, V. et al. Silica crystals and aluminum salts activate the NALP3 inflammasome through phagosomal destabilization. Nature Immunol 9, 847-856 (2008).
57. Eckmann, L. et al. Opposing functions of IKKβ during acute and chronic intestinal inflammation. Proc. Natl Acad. Sci. USA 105 15058-15063 (2008).
58. Ruocco, M. G. et al. IκB kinase (IKK)β, but not IKKα, is a critical mediator of osteoclast survival and is required for inflammation-induced bone loss. J. Exp. Med. 201, 1677-1687 (2005).
59. Suzuki, K. & Verma, I. M. Phosphorylation of SNAP-23 by IκB kinase 2 regulates mast cell degranulation. Cell 134, 485-495 (2008).
60. Collart, M. A., Baeuerle, P. & Vassalli, P. Regulation of tumor necrosis factor α transcription in macrophages: Involvement of four κB-like motifs and of constitutive and inducible forms of NF-κB. Mol. Cell. Biol. 10, 1498-1506 (1990).
61. Rhoades, K. L., Golub, S. H. & Economou, J. S. The regulation of the human tumor necrosis factor α promoter region in macrophage, T cell, and B cell lines. J. Biol. Chem. 267, 22102-22107 (1992).
62. Dumitru, C. D. et al. TNF-α induction by LPS is regulated posttranscriptionally via a Tpl2/ERK-dependent pathway. Cell 103, 1071-1083 (2000).
63. Kontoyiannis, D., Pasparakis, M., Pizarro, T. T., Cominelli, F. & Kollias, G. Impaired on/off regulation of TNF biosynthesis in mice lacking TNF AU-rich elements: Implications for joint and gut-associated immunopathologies. Immunity 10, 387-398 (1999).
64. Neininger, A. et al. MK2 targets AU-rich elements and regulates biosynthesis of tumor necrosis factor and interleukin-6 independently at different post-transcriptional levels. J. Biol. Chem. 277, 3065-3068 (2002).
65. Anderson, P. Post-transcriptional control of cytokine production. Nature Immunol. 9, 353-359 (2008).
66. Rousseau, S. et al. TPL2-mediated activation of ERK1 and ERK2 regulates the processing of pre-TNFα in LPS-stimulated macrophages. J. Cell Sci. 121, 149-154 (2008).
67. Janes, K. A., Reinhardt, H. C. & Yaffe, M. B. Cytokine-induced signaling networks prioritize dynamic range over signal strength. Cell 135, 343-354 (2008).
68. Noble, M. E., Endicott, J. A. & Johnson, L. N. Protein kinase inhibitors: Insights into drug design from structure. Science 303, 1800-1805 (2004).
69. Mader, M. et al. Imidazolyl benzimidazoles and imidazo[4,5-b]pyridines as potent p38α MAP kinase inhibitors with excellent in vivo antiinflammatory properties. Bioorg. Med. Chem. Lett. 18, 179-183 (2008).
70. Medicherla, S. et al. A selective p38α mitogen-activated protein kinase inhibitor reverses cartilage and bone destruction in mice with collagen-induced arthritis. J. Pharmacol. Exp. Ther. 318, 132-141 (2006).
71. Pheneger, J. et al. Effects of ARRY-797, a selective, potent p38 inhibitor, in in vivo models of inflammation and arthritis. Poster 929 ACR/ARHP Annual Scientific Meeting 2007 (Boston, Nov 6-11 2007).
72. McIntyre, K. W. et al. A highly selective inhibitor of IκB kinase, BMS-345541, blocks both joint inflammation and destruction in collagen-induced arthritis in mice. Arthritis Rheum. 48, 2652-2659 (2003).
73. Podolin, P. L. et al. Attenuation of murine collagen-induced arthritis by a novel, potent, selective small molecule inhibitor of IκB kinase 2, TPCA-1 (2-[(aminocarbonyl)amino]-5-(4-fluorophenyl)- 3-thio phenecarboxamide), occurs via reduction of proinflammatory cytokines and antigen-induced T cell proliferation. J. Pharmacol. Exp. Ther. 312, 373-381 (2005).
74. Dominguez, C., Powers, D. A. & Tamayo, N. p38 MAP kinase inhibitors: many are made, but few are chosen. Curr. Opin. Drug Discov. Devel. 8, 421-430 (2005).
75. Pettus, L. H. et al. 3-amino-7-phthalazinyl- benzoisoxazoles as a novel class of potent, selective, and orally available inhibitors of p38α mitogen-activated protein kinase. J. Med. Chem. 51, 6280-6292 (2008).
76. Cheung, M. et al. The identification of pyrazolo[1,5-a] pyridines as potent p38 kinase inhibitors. Bioorg. Med. Chem. Lett. 18 5428-5430 (2008).
77. Dambach, D. M. Potential adverse effects associated with inhibition of p38α/β MAP kinases. Curr. Top. Med. Chem. 5, 929-939 (2005).
78. Ding, C. Drug evaluation: VX-702, a MAP kinase inhibitor for rheumatoid arthritis and acute coronary syndrome. Curr. Opin. Investig. Drugs 7, 1020-1025 (2006).
79. Damjanov, N., Kauffman, R. & Spencer-Green, G. T. Safety and efficacy of VX-702, a p38 MAP kinase inhibitor, in rheumatoid arthritis. OP-0246 European League Against Rheumatism, Annual Congress (Paris, Jun 11-14 2008).
80. Xu, J. J., Hendriks, B. S., Zhao, J. & de Graaf, D. Multiple effects of acetaminophen and p38 inhibitors: Towards pathway toxicology. FEBS Lett. 582, 1276-1282 (2008).
81. Weinblatt, M. E. et al. Treatment of rheumatoid arthritis with a syk kinase inhibitor: A twelve-week, randomized, placebo-controlled trial. Arthritis Rheum. 58, 3309-3318 (2008).
82. Williams, W. et al. A randomized placebo-controlled study of INCB018424, a selective Janus kinase 1 & 2 (JAK1&2) inhibitor in rheumatoid arthritis (RA). Presentation 714 ACR/ARHP Annual Scientific Meeting 2008 (San Fransisco, Oct 24-29 2008).
83. Kremer, J. et al. The oral Jak Inhibitor CP-690,550 (CP) in combination with methotrexate (MTX) is efficacious, safe and well tolerated in patients with active rheumatoid arthiritis (RA) with an inadequate response to methotrexate alone. Presentation L13 ACR/ARHP Annual Scientific Meeting 2008 (San Fransisco, Oct 24-29 2008).
84. Punwani, N. et al. Initial efficacy and safety of topical INCB018424 cream, a selective Janus kinase 1 and 2 (JAK1&2) inhibitor in psoriasis. Poster presentation 17th Congress of European Academy of Dermatology and Venereology (Paris, Sep 18 2008).
85. Shibata, W. et al. c-Jun NH2-terminal kinase 1 is a critical regulator for the development of gastric cancer in mice. Cancer Res. 68, 5031-5039 (2008).
86. 2-terminal kinase 1 plays a critical role in intestinal homeostasis and tumor suppression. Am. J. Pathol. 171, 297-303 (2007).
87. Bulavin, D. V. et al. Initiation of a G2/M checkpoint after ultraviolet radiation requires p38 kinase. Nature 411, 102-107 (2001).
88. Cuadrado, A. et al. A new p38 MAP kinase-regulated transcriptional coactivator that stimulates p53-dependent apoptosis. EMBO J. 26 2115-2126 (2007).
89. Bulavin, D. V. & Fornace, A. J. Jr. p38 MAP kinase's emerging role as a tumor suppressor. Adv. Cancer Res. 92, 95-118 (2004).
90. Hui, L. et al. p38α suppresses normal and cancer cell proliferation by antagonizing the JNK - c-Jun pathway. Nature Genet. 39, 741-749 (2007).
91. Whitmarsh, A. J., Yang, S. H., Su, M. S., Sharrocks, A. D. & Davis, R. J. Role of p38 and JNK mitogen-activated protein kinases in the activation of ternary complex factors. Mol. Cell. Biol. 17, 2360-2371 (1997).
92. Muniyappa, H. & Das, K. C. Activation of c-Jun N-terminal kinase (JNK) by widely used specific p38 MAPK inhibitors SB202190 and SB203580: A MLK-3-MKK7-dependent mechanism. Cell Signal. 20, 675-683 (2008).
93. Cheung, P. C., Campbell, D. G., Nebreda, A. R. & Cohen, P. Feedback control of the protein kinase TAK1 by SAPK2a/p38α. EMBO J. 22 5793-5805 (2003).
94. Ambrosino, C. et al. Negative feedback regulation of MKK6 mRNA stability by p38α mitogen-activated protein kinase. Mol. Cell. Biol. 23, 370-381 (2003).
95. Ge, B. et al. MAPKK-independent activation of p38α mediated by TAB1-dependent autophosphorylation of p38α. Science 295, 1291-1294 (2002).
96. Salvador, J. M. et al. Alternative p38 activation pathway mediated by T cell receptor-proximal tyrosine kinases. Nature Immunol. 6 390-395 (2005).
97. Inoue, T. et al. Mitogen-activated protein kinase kinase 3 is a pivotal pathway regulating p38 activation in inflammatory arthritis. Proc. Natl Acad. Sci. USA 103, 5484-5489 (2006).
98. Yoshizawa, T. et al. Decreased passive K/BxN-induced arthritis in MKK6 deficient mice: Novel uncoupling of p38 activation from cytokine regulation Poster 673 ACR/ARHP Annual Scientific Meeting 2007 (Boston, Nov 6-11 2007).
99. Hammaker, D. R., Boyle, D. L. & Firestein, G. S. Differential regulation of cytokines by MKK3 and MKK6 in synoviocytes: Complementary signaling pathways. Poster 131 ACR/ARHP Annual Scientific Meeting 2007 (Boston, Nov 6-11 2007).
100. Brancho, D. et al. Mechanism of p38 MAP kinase activation in vivo. Genes Dev. 17, 1969-1978 (2003).
101. Kotlyarov, A. et al. Distinct cellular functions of MK2. Mol. Cell. Biol. 22, 4827-4835 (2002).
102. Hegen, M., Gaestel, M., Nickerson-Nutter, C. L., Lin, L. L. & Telliez, J. B. MAPKAP kinase 2-deficient mice are resistant to collagen-induced arthritis. J. Immunol. 177, 1913-1917 (2006).
103. Lehner, M. D. et al. Mitogen-activated protein kinase-activated protein kinase 2-deficient mice show increased susceptibility to Listeria monocytogenes infection. J. Immunol. 168, 4667-4673 (2002).
104. Manke, I. A. et al. MAPKAP kinase-2 is a cell cycle checkpoint kinase that regulates the G2/M transition and S phase progression in response to UV irradiation. Mol. Cell 17, 37-48 (2005).
105. Reinhardt, H. C., Aslanian, A. S., Lees, J. A. & Yaffe, M. B. p53-deficient cells rely on ATM- and ATR-mediated checkpoint signaling through the p38MAPK/MK2 pathway for survival after DNA damage. Cancer Cell 11, 175-189 (2007).
106. Anderson, D. R. et al. Aminocyanopyridine inhibitors of mitogen activated protein kinase-activated protein kinase 2 (MK-2). Bioorg. Med. Chem. Lett. 15, 1587-1590 (2005).
107. Wu, J. P. et al. The discovery of carboline analogs as potent MAPKAP-K2 inhibitors. Bioorg. Med. Chem. Lett. 17, 4664-4669 (2007).
108. Schlapbach, A. et al. Pyrrolo-pyrimidones: A novel class of MK2 inhibitors with potent cellular activity. Bioorg. Med. Chem. Lett. 18, 6142-6146 (2008).
109. May, M. J. et al. Selective inhibition of NF-κB activation by a peptide that blocks the interaction of NEMO with the IκB kinase complex. Science 289, 1550-1554 (2000).
110. Jimi, E. et al. Selective inhibition of NF-κ B blocks osteoclastogenesis and prevents inflammatory bone destruction in vivo. Nature Med. 10, 617-624 (2004).
111. Dai, S., Hirayama, T., Abbas, S. & Abu-Amer, Y. The IκB kinase (IKK) inhibitor, NEMO-binding domain peptide, blocks osteoclastogenesis and bone erosion in inflammatory arthritis. J. Biol. Chem. 279, 37219-37222 (2004).
112. Strickland, I. & Ghosh, S. Use of cell permeable NBD peptides for suppression of inflammation. Ann. Rheum. Dis. 65 (Suppl. 3), iii75-iii82 (2006).
113. Gaestel, M. & Kracht, M. Peptides as signaling inhibitors for mammalian MAPK kinase cascades. Curr. Pharm. Des. (in the press).
114. Tas, S. W. et al. Local treatment with the selective IκB kinase β inhibitor NEMO-binding domain peptide ameliorates synovial inflammation. Arthritis Res. Ther. 8, R86 (2006).
115. Dickens, M. et al. A cytoplasmic inhibitor of the JNK signal transduction pathway. Science 277, 693-696 (1997).
116. Waeber, G. et al. The gene MAPK8IP1, encoding islet-brain-1, is a candidate for type 2 diabetes. Nature Genet. 24, 291-295 (2000).
117. Whitmarsh, A. J., Cavanagh, J., Tournier, C., Yasuda, J. & Davis, R. J. A mammalian scaffold complex that selectively mediates MAP kinase activation. Science 281, 1671-1674 (1998).
118. Bonny, C., Oberson, A., Negri, S., Sauser, C. & Schorderet, D. F. Cell-permeable peptide inhibitors of JNK: Novel blockers of β-cell death. Diabetes 50, 77-82 (2001).
119. Kaneto, H. et al. Possible novel therapy for diabetes with cell-permeable JNK-inhibitory peptide. Nature Med. 10, 1128-1132 (2004).
120. Pirvola, U. et al. Rescue of hearing, auditory hair cells, and neurons by CEP-1347/KT7515, an inhibitor of c-Jun N-terminal kinase activation. J. Neurosci. 20, 43-50 (2000).
121. Heo, Y. S. et al. Structural basis for the selective inhibition of JNK1 by the scaffolding protein JIP1 and SP600125. EMBO J. 23 2185-2195 (2004).
122. Stebbins, J. L. et al. Identification of a new JNK inhibitor targeting the JNK-JIP interaction site. Proc. Natl Acad. Sci. USA 105, 16809-16813 (2008).
123. Kamata, H. et al. Reactive oxygen species promote TNFα-induced death and sustained JNK activation by inhibiting MAP kinase phosphatases. Cell 120, 649-661 (2005).
124. Papa, S. et al. Gadd45β mediates the NF-κB suppression of JNK signalling by targeting MKK7/JNKK2. Nature Cell Biol. 6, 146-153 (2004).
125. Tang, G. et al. Inhibition of JNK activation through NF-κB target genes. Nature 414, 313-317 (2001).
126. Gorska, M. M. et al. MK2 controls the level of negative feedback in the NF-κB pathway and is essential for vascular permeability and airway inflammation. J. Exp. Med. 204, 1637-1652 (2007).
127. Basak, S. & Hoffmann, A. Crosstalk via the NF-κB signaling system. Cytokine Growth Factor Rev. 19, 187-197 (2008).
128. Oda, K. & Kitano, H. A comprehensive map of the Toll-like receptor signaling network. Mol. Syst. Biol. 2, 2006.0015 (2006).
129. Glass, C. K. & Ogawa, S. Combinatorial roles of nuclear receptors in inflammation and immunity. Nature Rev. Immunol. 6, 44-55 (2006).
130. Abraham, S. M. et al. Antiinflammatory effects of dexamethasone are partly dependent on induction of dual specificity phosphatase 1. J. Exp. Med. 203, 1883-1889 (2006).
131. Bruna, A., Nicolas, M., Munoz, A., Kyriakis, J. M. & Caelles, C. Glucocorticoid receptor-JNK interaction mediates inhibition of the JNK pathway by glucocorticoids. EMBO J. 22, 6035-6044 (2003).
132. Kim, M. J. et al. Negative regulation of SEK1 signaling by serum- and glucocorticoid-inducible protein kinase 1. EMBO J. 26, 3075-3085 (2007).
133. Beck, I. M. et al. Altered subcellular distribution of MSK1 induced by glucocorticoids contributes to NF-κB inhibition. EMBO J. 27, 1682-1693 (2008).
134. McCoy, C. E., Carpenter, S., Palsson-McDermott, E. M., Gearing, L. J. & O'Neill, L. A. Glucocorticoids inhibit IRF3 phosphorylation in response to Toll-like receptor-3 and -4 by targeting TBK1 activation. J. Biol. Chem. 283, 14277-14285 (2008).
135. Miyachi, K. et al. Efficacy of imatinib mesylate (STI571) treatment for a patient with rheumatoid arthritis developing chronic myelogenous leukemia. Clin. Rheumatol. 22, 329-332 (2003).
136. Ames, P. R., Aye, W. W., Beatty, C. & O'Reilly, D. Imatinib treatment of seropositive arthritis in a young woman with chronic myeloid leukemia. J. Rheumatol. 35, 1682 (2008).
137. Dinarello, C. A. Historical insights into cytokines. Eur. J. Immunol. 37, S34-S45 (2007).
138. Costa, M. F., Said, N. R. & Zimmermann, B. Drug-induced lupus due to anti-tumor necrosis factor α agents. Semin. Arthritis Rheum. 37 381-387 (2008).
139. Farasat, S., Aksentijevich, I. & Toro, J. R. Autoinflammatory diseases: clinical and genetic advances. Arch. Dermatol. 144, 392-402 (2008).
140. Pascual, V. et al. How the study of children with rheumatic diseases identified interferon-α and interleukin-1 as novel therapeutic targets. Immunol. Rev. 223, 39-59 (2008).
141. Nixon, R., Bansback, N. & Brennan, A. The efficacy of inhibiting tumour necrosis factor α and interleukin 1 in patients with rheumatoid arthritis: A meta-analysis and adjusted indirect comparisons. Rheumatology (Oxford) 46, 1140-1147 (2007).
142. Lovell, D. J. et al. Adalimumab with or without methotrexate in juvenile rheumatoid arthritis. N. Engl. J. Med. 359, 810-820 (2008).
143. Bennett, A. N. et al. Sustained response to anakinra in ankylosing spondylitis. Rheumatology (Oxford) 47, 223-224 (2008).
144. Peyrin-Biroulet, L. et al. Efficacy and safety of tumor necrosis factor antagonists in Crohn's disease: Meta-analysis of placebo-controlled trials. Clin. Gastroenterol. Hepatol. 6, 644-653 (2008).
145. Brimhall, A. K., King, L. N., Licciardone, J. C., Jacobe, H. & Menter, A. Safety and efficacy of alefacept, efalizumab, etanercept and infliximab in treating moderate to severe plaque psoriasis: A meta-analysis of randomized controlled trials. Br. J. Dermatol. 159, 274-285 (2008).
146. Josselin, L. et al. Infliximab efficacy and safety against refractory systemic necrotising vasculitides: Long-term follow-up of 15 patients. Ann. Rheum. Dis. 67, 1343-1346 (2008).
147. Manning, G., Whyte, D. B., Martinez, R., Hunter, T. & Sudarsanam, S. The protein kinase complement of the human genome. Science 298, 1912-1934 (2002).
148. Varjosalo, M. et al. Application of active and kinase-deficient kinome collection for identification of kinases regulating hedgehog signaling. Cell 133, 537-548 (2008).
149. Caenepeel, S., Charydczak, G., Sudarsanam, S., Hunter, T. & Manning, G. The mouse kinome: Discovery and comparative genomics of all mouse protein kinases. Proc. Natl Acad. Sci. USA 101, 11707-11712 (2004).
150. Tanoue, T. & Nishida, E. Molecular recognitions in the MAP kinase cascades. Cell Signal. 15, 455-462 (2003).
151. Takekawa, M., Tatebayashi, K. & Saito, H. Conserved docking site is essential for activation of mammalian MAP kinase kinases by specific MAP kinase kinase kinases. Mol. Cell 18, 295-306 (2005).
152. Dimitri, C. A., Dowdle, W., MacKeigan, J. P., Blenis, J. & Murphy, L. O. Spatially separate docking sites on ERK2 regulate distinct signaling events in vivo. Curr. Biol. 15, 1319-1324 (2005).
153. O'Neill, L. A. & Bowie, A. G. The family of five: TIR-domain-containing adaptors in Toll-like receptor signalling. Nature Rev. Immunol. 7, 353-364 (2007).
154. O'Neill, L. A. When signaling pathways collide: Positive and negative regulation of Toll-like receptor signal transduction. Immunity 29, 12-20 (2008).
155. Han, J. & Ulevitch, R. J. Limiting inflammatory responses during activation of innate immunity. Nature Immunol. 6, 1198-1205 (2005).
156. Chan, C., Li, L., McCall, C. E. & Yoza, B. K. Endotoxin tolerance disrupts chromatin remodeling and NF-κB transactivation at the IL-1β promoter. J. Immunol. 175, 461-468 (2005).
157. Liang, M. D., Zhang, Y., McDevit, D., Marecki, S. & Nikolajczyk, B. S. The interleukin-1β gene is transcribed from a poised promoter architecture in monocytes. J. Biol. Chem. 281, 9227-9237 (2006).
158. Nicholas, C. et al. Apigenin blocks lipopolysaccharide-induced lethality in vivo and proinflammatory cytokines expression by inactivating NF-κB through the suppression of p65 phosphorylation. J. Immunol. 179, 7121-7127 (2007).
159. Frevel, M. A. et al. p38 mitogen-activated protein kinase-dependent and -independent signaling of mRNA stability of AU-rich element-containing transcripts. Mol. Cell. Biol. 23, 425-436 (2003).
160. Meylan, E., Tschopp, J. & Karin, M. Intracellular pattern recognition receptors in the host response. Nature 442, 39-44 (2006).
161. Gabel, C. A. P2 purinergic receptor modulation of cytokine production. Purinergic Signal. 3, 27-38 (2007).
162. Kotlyarov, A. et al. MAPKAP kinase 2 is essential for LPS-induced TNF-α biosynthesis. Nature Cell Biol. 1, 94-97 (1999).
163. Wang, Z. et al. Crystal structures of IRAK-4 kinase in complex with inhibitors: A serine/threonine kinase with tyrosine as a gatekeeper. Structure 14, 1835-1844 (2006).
164. Hillig, R. C. et al. Structural basis for a high affinity inhibitor bound to protein kinase MK2. J. Mol. Biol. 369, 735-745 (2007).
165. Lucet, I. S. et al. The structural basis of Janus kinase 2 inhibition by a potent and specific pan-Janus kinase inhibitor. Blood 107, 176-183 (2006).
166. Ohori, M. et al. Role of a cysteine residue in the active site of ERK and the MAPKK family. Biochem. Biophys. Res. Commun. 353 633-637 (2007).
167. Liu, S., Sun, J. P., Zhou, B. & Zhang, Z. Y. Structural basis of docking interactions between ERK2 and MAP kinase phosphatase 3. Proc. Natl Acad. Sci. USA 103, 5326-5331 (2006).
168. Alford, K. A. et al. Heat shock protein 27 functions in inflammatory gene expression and transforming growth factor-β-activated kinase-1 (TAK1)-mediated signaling. J. Biol. Chem. 282, 6232-6241 (2007).
169. Kanakaraj, P. et al. Interleukin (IL)-1 receptor-associated kinase (IRAK) requirement for optimal induction of multiple IL-1 signaling pathways and IL-6 production. J. Exp. Med. 187, 2073-2079 (1998).
170. Suzuki, N. et al. Severe impairment of interleukin-1 and Toll-like receptor signalling in mice lacking IRAK-4. Nature 416, 750-756 (2002).
171. Cao, Y. et al. IKKα provides an essential link between RANK signaling and cyclin D1 expression during mammary gland development. Cell 107, 763-775 (2001).
172. Yang, J. et al. Mekk3 is essential for early embryonic cardiovascular development. Nature Genet. 24, 309-313 (2000).
173. Huang, Q. et al. Differential regulation of interleukin 1 receptor and Toll-like receptor signaling by MEKK3. Nature Immunol. 5 98-103 (2004).
174. Constant, S. L. et al. JNK1 is required for T cell-mediated immunity against Leishmania major infection. J. Immunol. 165, 2671-2676 (2000).
175. 2-terminal kinase 1 plays a critical role in intestinal homeostasis and tumor suppression. Am. J. Pathol. 171, 297-303 (2007).
176. 2-terminal kinase-1 in mice enhances skin tumor development by 12-O-tetradecanoylphorbol-13-acetate. Cancer Res. 62, 1343-1348 (2002).
177. Han, Z., Chang, L., Yamanishi, Y., Karin, M. & Firestein, G. S. Joint damage and inflammation in c-Jun N-terminal kinase 2 knockout mice with passive murine collagen-induced arthritis. Arthritis Rheum. 46 818-823 (2002).
178. Komatsu, Y. et al. Targeted disruption of the Tab1 gene causes embryonic lethality and defects in cardiovascular and lung morphogenesis. Mech. Dev. 119, 239-249 (2002).
179. Kajino-Sakamoto, R. et al. Enterocyte-derived TAK1 signaling prevents epithelium apoptosis and the development of ileitis and colitis. J. Immunol. 181, 1143-1152 (2008).
180. Omori, E., Morioka, S., Matsumoto, K. & Ninomiya-Tsuji, J. TAK1 regulates reactive oxygen species and cell death in keratinocytes, which is essential for skin integrity. J. Biol. Chem. 283, 26161-26168 (2008).
181. Adams, R. H. et al. Essential role of p38α MAP kinase in placental but not embryonic cardiovascular development. Mol. Cell 6, 109-116 (2000).
182. Perdiguero, E. et al. Genetic analysis of p38 MAP kinases in myogenesis: Fundamental role of p38α in abrogating myoblast proliferation. EMBO J. 26, 1245-1256 (2007).
183. Tanaka, M. et al. Embryonic lethality, liver degeneration, and impaired NF-κB activation in IKK-β-deficient mice. Immunity 10, 421-429 (1999).
184. Broide, D. H. et al. Allergen-induced peribronchial fibrosis and mucus production mediated by IκB kinase β-dependent genes in airway epithelium. Proc. Natl Acad. Sci. USA 102, 17723-17728 (2005).
185. Ninomiya-Tsuji, J. et al. A resorcylic acid lactone, 5Z-7-oxozeaenol, prevents inflammation by inhibiting the catalytic activity of TAK1 MAPK kinase kinase. J. Biol. Chem. 278, 18485-18490 (2003).
186. Miampamba, M. et al. RDEA119, a potent and highly selective MEK1/2 inhibitor is beneficial in dextran sulfate sodium (DSS)-induced chronic colitis in mice. The ACG Annual Scientific Meeting and Postgraduate Course (Orlando, Oct 3-8 2008).
187. George, D. et al. Discovery of thieno[2,3-c]pyridines as potent COT inhibitors. Bioorg. Med. Chem. Lett. 18, 4952-4955 (2008).
188. Hall, J. P. et al. Pharmacologic inhibition of tpl2 blocks inflammatory responses in primary human monocytes, synoviocytes, and blood. J. Biol. Chem. 282, 33295-33304 (2007).
189. Han, Z. et al. c-Jun N-terminal kinase is required for
190. Fridman, J. et al. Efficacy and tolerability of novel JAK inhibitors in animal models of rheumatoid arthritis. Poster 1771 ACR/ ARHP Annual Scientific Meeting 2007 (Boston, Nov 6-11 2008).
191. Lin, T. A. et al. Selective Itk inhibitors block T-cell activation and murine lung inflammation. Biochemistry 43, 11056-11062 (2004).
192. Pine, P. R. et al. Inflammation and bone erosion are suppressed in models of rheumatoid arthritis following treatment with a novel Syk inhibitor. Clin. Immunol. 124, 244-257 (2007).
193. Farmer, L. J. et al. Discovery and SAR of novel 4-thiazolyl-2-phenylaminopyrimidines as potent inhibitors of spleen tyrosine kinase (SYK). Bioorg. Med. Chem. Lett. 18, 6231-6235 (2008).
194. Stojanovic, I. et al. In vitro, ex vivo and in vivo immunopharmacological activities of the isoxazoline compound VGX-1027: modulation of cytokine synthesis and prevention of both organ-specific and systemic autoimmune diseases in murine models. Clin. Immunol. 123, 311-323 (2007).
195. Gaestel, M., Mengel, A., Bothe, U. & Asadullah, K. Protein kinases as small molecule inhibitor targets in inflammation. Curr. Med. Chem. 14, 2214-2234 (2007).